<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112863</url>
  </required_header>
  <id_info>
    <org_study_id>1015536</org_study_id>
    <nct_id>NCT03112863</nct_id>
  </id_info>
  <brief_title>Comparison of the Cosmetic Effects of Bakuchiol and Retinol</brief_title>
  <official_title>Comparison of the Cosmetic Effects of Bakuchiol and Retinol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be assigned to a retinoid cream or bakuchiol to compare the cosmetic effects.&#xD;
      This will take place over a 12 week period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bakuchiol is a phytochemical that has demonstrated cutaneous antiageing effects when applied&#xD;
      topically. Early studies have suggested that bakuchiol is a functional analogue of topical&#xD;
      retinoids, as both compounds have been shown to induce similar gene expression in the skin&#xD;
      and lead to improvement of cutaneous photodamage. No in vivo studies have compared the two&#xD;
      compounds for efficacy and side-effects.&#xD;
&#xD;
      The aim of this study is to compare the cosmetic effects of Bakuchiol to Retinol over a&#xD;
      12-week period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 24, 2017</start_date>
  <completion_date type="Actual">March 1, 2019</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind randomized study comparing the effect of bakuchiol and retinoid</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Wrinkle Appearance</measure>
    <time_frame>12 week</time_frame>
    <description>Assessed using image analysis based assessment of wrinkle severity (depth and length).&#xD;
The primary outcome measure was image-analysis-based assessment of wrinkle severity and pigmentation at 12 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Change in Appearance of Skin Pigmentation</measure>
    <time_frame>12 week</time_frame>
    <description>Assessed using image analysis based assessment of facial pigment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Reports of Stinging, Burning, Itching</measure>
    <time_frame>Assessed at Week 4, 8, and 12.</time_frame>
    <description>Subjective tolerability assessment of stinging, burning, itching. Secondary outcome measures included redness, participant-reported tolerability (itching, burning and stinging) and in-person clinical assessments (pigmentation, scaling and erythema) throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Reports of Facial Erythema Assessment</measure>
    <time_frame>week 4, week 8 and week 12</time_frame>
    <description>Image analysis based assessment of facial erythema</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Wrinkle</condition>
  <condition>Photoaging</condition>
  <arm_group>
    <arm_group_label>Bakuchiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bakuchiol 0.5% applied to face twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5% retinol applied to face nightly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bakuchiol</intervention_name>
    <description>This group will receive bakuchiol</description>
    <arm_group_label>Bakuchiol</arm_group_label>
    <other_name>Bakuchiol 0.5%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retinol</intervention_name>
    <description>This group will receive retinol</description>
    <arm_group_label>Retinol</arm_group_label>
    <other_name>Retinol %</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ Individuals aged 30-55&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  Individuals who are not yet adults (infants, children, teenagers)&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Those with acne, eczema, seborrheic dermatitis, rosacea or polycystic ovarian syndrome&#xD;
&#xD;
          -  Those who have used isotretinoin in the last 6 months&#xD;
&#xD;
          -  Those who have used products containing salicylic acid, beta hydroxyl acids or&#xD;
             vitamins A, C, or E in the last 14 days&#xD;
&#xD;
          -  Those who have used topical antibiotics or topical retinoids in the last 30 days&#xD;
&#xD;
          -  Those who are currently smoking or have smoked within the past 3 years.&#xD;
&#xD;
          -  Those who have had a recent surgical or cosmetic procedure in the last 3 months that&#xD;
             can affect facial wrinkles or facial hyperpigmentation, such as botulinum toxin&#xD;
             injections, chemical peels, laser based therapies to the face, or face lift surgeries&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raja Sivamani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis Department of Dermatology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <results_first_submitted>July 9, 2021</results_first_submitted>
  <results_first_submitted_qc>October 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2021</results_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Retinol palmitate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03112863/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03112863/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bakuchiol</title>
          <description>Bakuchiol 0.5% applied to face twice daily&#xD;
Bakuchiol: This group will receive bakuchiol</description>
        </group>
        <group group_id="P2">
          <title>Retinol</title>
          <description>0.5% retinol applied to face nightly&#xD;
Retinol: This group will receive retinol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Bakuchiol 21 participants were analyzed Retinol 23 participants were analyzed</population>
      <group_list>
        <group group_id="B1">
          <title>Bakuchiol</title>
          <description>Bakuchiol 0.5% applied to face twice daily&#xD;
Bakuchiol: This group will receive bakuchiol</description>
        </group>
        <group group_id="B2">
          <title>Retinol</title>
          <description>0.5% retinol applied to face nightly&#xD;
Retinol: This group will receive retinol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>We did not include ethnicity data in this study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Wrinkle Appearance</title>
        <description>Assessed using image analysis based assessment of wrinkle severity (depth and length).&#xD;
The primary outcome measure was image-analysis-based assessment of wrinkle severity and pigmentation at 12 weeks.</description>
        <time_frame>12 week</time_frame>
        <population>21 participants were analyzed in the Bakuchiol group and 23 participants were analyzed in the Retinol group.</population>
        <group_list>
          <group group_id="O1">
            <title>Bakuchiol</title>
            <description>Bakuchiol 0.5% applied to face twice daily&#xD;
Bakuchiol: This group will receive bakuchiol</description>
          </group>
          <group group_id="O2">
            <title>Retinol</title>
            <description>0.5% retinol applied to face nightly&#xD;
Retinol: This group will receive retinol</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Wrinkle Appearance</title>
          <description>Assessed using image analysis based assessment of wrinkle severity (depth and length).&#xD;
The primary outcome measure was image-analysis-based assessment of wrinkle severity and pigmentation at 12 weeks.</description>
          <population>21 participants were analyzed in the Bakuchiol group and 23 participants were analyzed in the Retinol group.</population>
          <units>percentage of reduced fine wrinkles</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Change in Appearance of Skin Pigmentation</title>
        <description>Assessed using image analysis based assessment of facial pigment</description>
        <time_frame>12 week</time_frame>
        <population>Pigmentation was assessed through clinical grading and through facial analysis of the surface area of involvement and overall pigment intensity.</population>
        <group_list>
          <group group_id="O1">
            <title>Bakuchiol</title>
            <description>Bakuchiol 0.5% applied to face twice daily&#xD;
Bakuchiol: This group will receive bakuchiol</description>
          </group>
          <group group_id="O2">
            <title>Retinol</title>
            <description>0.5% retinol applied to face nightly&#xD;
Retinol: This group will receive retinol</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change in Appearance of Skin Pigmentation</title>
          <description>Assessed using image analysis based assessment of facial pigment</description>
          <population>Pigmentation was assessed through clinical grading and through facial analysis of the surface area of involvement and overall pigment intensity.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Reports of Stinging, Burning, Itching</title>
        <description>Subjective tolerability assessment of stinging, burning, itching. Secondary outcome measures included redness, participant-reported tolerability (itching, burning and stinging) and in-person clinical assessments (pigmentation, scaling and erythema) throughout the study.</description>
        <time_frame>Assessed at Week 4, 8, and 12.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bakuchiol</title>
            <description>Bakuchiol 0.5% applied to face twice daily&#xD;
Bakuchiol: This group will receive bakuchiol</description>
          </group>
          <group group_id="O2">
            <title>Retinol</title>
            <description>0.5% retinol applied to face nightly&#xD;
Retinol: This group will receive retinol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Reports of Stinging, Burning, Itching</title>
          <description>Subjective tolerability assessment of stinging, burning, itching. Secondary outcome measures included redness, participant-reported tolerability (itching, burning and stinging) and in-person clinical assessments (pigmentation, scaling and erythema) throughout the study.</description>
          <units>reports</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Reports of Facial Erythema Assessment</title>
        <description>Image analysis based assessment of facial erythema</description>
        <time_frame>week 4, week 8 and week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bakuchiol</title>
            <description>Bakuchiol 0.5% applied to face twice daily&#xD;
Bakuchiol: This group will receive bakuchiol</description>
          </group>
          <group group_id="O2">
            <title>Retinol</title>
            <description>0.5% retinol applied to face nightly&#xD;
Retinol: This group will receive retinol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Reports of Facial Erythema Assessment</title>
          <description>Image analysis based assessment of facial erythema</description>
          <units>reports</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Subjects were no assessed for SAE or Mortality.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bakuchiol</title>
          <description>Bakuchiol 0.5% applied to face twice daily&#xD;
Bakuchiol: This group will receive bakuchiol</description>
        </group>
        <group group_id="E2">
          <title>Retinol</title>
          <description>0.5% retinol applied to face nightly&#xD;
Retinol: This group will receive retinol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Iryna Rybak</name_or_title>
      <organization>UC Davis Dermatology</organization>
      <phone>916-551-2636</phone>
      <email>irybak@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

